Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). (Q48287350)
Jump to navigation
Jump to search
scientific article published in March 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). |
scientific article published in March 2013 |
Statements
1 reference
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). (English)
1 reference
1 reference
G Chen
1 reference
J Feng
1 reference
C Zhou
1 reference
X-Q Liu
1 reference
C Wang
1 reference
S Zhang
1 reference
J Wang
1 reference
S Zhou
1 reference
S Ren
1 reference
S Lu
1 reference
L Zhang
1 reference
C-P Hu
1 reference
C Hu
1 reference
Y Luo
1 reference
L Chen
1 reference
M Ye
1 reference
J Huang
1 reference
X Zhi
1 reference
Y Zhang
1 reference
Q Xiu
1 reference
J Ma
1 reference
L Zhang
1 reference
C You
1 reference
1 March 2013
1 reference
1 reference
24
1 reference
6
1 reference
1615-1622
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference